How to Buy Assertio Holdings Stock
Assertio Holdings Inc
Assertio Holdings, Inc. , a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation.
Assertio Holdings stock last closed at $6.35, down 1.24% from the previous day, and has increased 102.88% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 1.37 percentage points. Assertio Holdings stock is currently +206.02% from its 52-week low of $2.08, and -20.72% from its 52-week high of $8.01.
As of Jun 2, 2023, there are 55.66M ASRT shares outstanding. The market capitalization of ASRT is $353.47M. In the last 24 hours, 967,421 ASRT shares were traded.
How to Buy Assertio Holdings Stock
Wondering how to invest in Assertio Holdings stock? Here's how.
- Figure out where to buy Assertio Holdings stock: You need to decide on an online brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you choose where to buy Assertio Holdings stock.
- Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit funds into your brokerage account: Pick your method of payment and add your info.
- Evaluate Assertio Holdings stock: The Assertio Holdings ticker symbol is ASRT. Is Assertio Holdings stock a good investment? Should you buy shares of ASRT? How do ASRT's underlying business fundamentals look? Do top analysts think Assertio Holdings is a good buy? Why has ASRT's stock price moved recently? (Hint: Our stock market research website can help you decide if ASRT is a good stock to buy).
- Place your ASRT trade: Decide if you will purchase ASRT shares at the current market price or use a limit order to purchase ASRT stock at a particular price.
- Track your ASRT position: Create a watchlist to track your new investment in Assertio Holdings stock.
Step 1: Figure out where to buy Assertio Holdings stock
You will need a brokerage account to access the NASDAQ market and buy ASRT shares.
Our preferred brokerage: eToro
Based on our experience, eToro is the best place to buy stocks. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global markets: From Tech to Real Estate, New York to Tokyo — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by opening an account with eToro now.
Open eToro AccountStep 2: Create a brokerage account
Now that you've picked the best brokerage, you'll need to fill out some personal information so you are able to invest in ASRT today.
How to Create a New Investment Account on eToro
- Click here to get started.
- Provide your personal data to start your new brokerage account.
- Send your details by pressing the "Create Account" button.
Step 3: Deposit funds into your brokerage account
Now that you've opened your account on the best stock market app for beginners, your next step is to transfer the money for your investment:
Watch the tutorial below if you need help depositing money into your brokerage account.
Step 4: Evaluate Assertio Holdings stock
Once you have decided on the best place to buy Assertio Holdings stock, it's very important to research their stock before you buy, so you actually understand the risk as well as the opportunity.
Assertio Holdings quick stats
Fundamentals of Assertio Holdings
WallStreetZen was built to help everyday investors do better fundamental analysis.
You can view all of the due diligence checks on ASRT's stock page.
Is ASRT stock properly valued?
Investors use many financial metrics, analyses, models, and charts to gauge ASRT's fair value.
Using relative valuations metrics:
- ASRT could be undervalued based on its P/E ratio of 3.07x, relative to Drug Manufacturers - Specialty & Generic industry P/E ratio of 14.9x
- ASRT could be undervalued based on its P/B ratio of 1.41x, relative to Drug Manufacturers - Specialty & Generic industry P/B ratio of 1.79x
- ASRT could be undervalued based on its PEG ratio of 0x
You can do more valuation analysis on ASRT's stock here.
A look at ASRT Cashflows and Balance Sheet
Passed Financial Due Diligence Checks:
- ASRT profit margin has gone up from 2.7% to 59.9% in the past year.
- Total ASRT debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the ASRT balance sheet.
- ASRT's operating cash flow of $73.89M allows it to safely service it's debt of $38.62M.
- There are more short-term assets than long-term liabilities on the ASRT balance sheet.
Failed Financial Due Diligence Checks:
- ASRT has a relatively high debt to equity ratio of 0.65.
- ASRT earnings of $22.55M is not enough to cover its interest payments.
Is it a good time to buy Assertio Holdings stock, according to Wall Street analysts?
Out of 2 sell side analysts who research ASRT, the consensus analyst rating on Assertio Holdings is a Strong Buy
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Latest ASRT Analyst Upgrades/Downgrades
Thomas Flaten, a top 28% analyst from Lake Street maintains ASRT with a strong buy rating and raises their ASRT price target from $8.00 to $9.00, on May 10, 2023.
Maintaining his Strong Buy rating, Flaten raised his price target on Assertio Holdings, Inc. by 12.5% following the release of the company's Q1 2023 earnings report on 2023/05/09.
Q1 results were "well ahead" of his estimates and management raised its guidance, the analyst summarized.
He expects the Spectrum acquisition to close in Q3 of this year as scheduled, Flaten added.
For Q1 2023, Assertio Holdings reported:
- Loss per share of $0.07, which missed the Zacks Consensus Estimate of EPS of $0.13 and Q1 2022's $0.20 EPS.
- Revenue of $42.47M, which beat the Zacks Consensus Estimate by 12.40% and Q1 2022's $36.54M by 16.2%.
- Adjusted EBITDA of $25.6B, up 7.1% from Q1 2022's $23.9M.
For FY 2023, management guided:
- Net Product Sales of $157.M to $167M, up from the previously guided $150M to $160M.
- Adjusted EBITDA of $90M to $98M, up from the previously guided $85M to $93M.
President & CEO Dan Peisert commented: "A little over two years ago we adopted a strategy to increase profitability, improve our balance sheet, reduce our cost of capital, diversify our business and create internal and external opportunities for growth.
“Through the adoption of our innovative digital non-personal sales model, significant growth and cash flow, the refinancing of our indebtedness and our most recent completed acquisition of Sympazan, we have achieved most of what we set out to do and put Assertio on a pathway for significant and sustainable growth over the coming years.”
Hamed Khorsand, a top 8% analyst from BWS Financial maintains ASRT with a buy rating and raises their ASRT price target from $8.00 to $10.00, on May 10, 2023.
You can dive deeper into what analysts are forecasting on the Assertio Holdings stock forecast page.
ASRT Technicals
ASRT Performance Metrics
Last year, ASRT earnings were $97.08M. During the last one years, ASRT's earnings have increased by 2,857.14% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 12.85%.
Last year, ASRT revenue was $162.16M. Over the last 5 year, ASRT's revenue has increased by -17.28% per year. This was slower than the Drug Manufacturers - Specialty & Generic industry average of 15.35%.
You can analyze ASRT's earnings and revenue performance here.
Latest Insiders Trades at ASRT
In the past year, executives and large shareholders at ASRT have sold more shares than they have bought.
Heather L. Mason, Director of ASRT, was the latest ASRT insider to sell. They sold $652,055.66 worth of ASRT shares on May 19, 2023.
Learn more about who owns ASRT shares here.
Does ASRT provide a stable income stream?
No, Assertio Holdings doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Place your ASRT trade
You have two primary options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are mostly the easiest way to buy. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at an exact dollar amount, place a limit order.
Click the Open Trade button and your broker will place the order.
If you need additional info about investing in stocks on eToro, click the helpful video below:
Step 6: Track your ASRT position
Now that you own some shares in ASRT, you'll want to stay up-to-date on your company.
Add ASRT to a watchlist to track your ASRT stock.
ASRT Feed
How to Buy Stock in Assertio Holdings
To summarize, here are the 6 steps to buy Assertio Holdings stock:
- Figure out where to buy Assertio Holdings stock
- Create a brokerage account
- Deposit funds into your brokerage account
- Evaluate Assertio Holdings stock
- Place your ASRT trade
- Track your ASRT position
If you need a brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to watch your investment in Assertio Holdings, get started below.
More "How To" Guides You May Find Useful
FAQ
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.